Physician profile
Alexandra Stewart
NPI 1558736603
$5,109.44
in general payments reported to CMS, 2019-2025
28 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $360 · 2022: $97.15 · 2023: $894 · 2024: $2,023 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,386 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,385.63 |
| Education | $266.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $992.90 | 2021-2025 | Tremfya |
| Genzyme Corporation | $531.29 | 2023-2025 | |
| Abbvie INC. | $502.45 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $471.04 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.62 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $300.68 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $279.26 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $240.08 | 2022-2025 | Opzelura |
| Amgen INC. | $202.46 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $162.72 | 2021-2025 | Bimzelx |
| Pfizer INC. | $129.05 | 2024-2025 | |
| Galderma Laboratories, L.P. | $127.92 | 2023-2025 | Oracea, Epsolay, Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.47 | 2024 | Spevigo |
| Sun Pharmaceutical Industries INC. | $107.88 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Journey Medical Corporation | $74.09 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.54 | 2023-2025 | Jublia, Cabtreo, Siliq |
| Leo Pharma INC. | $54.93 | 2023-2025 | Adbry |
| Biofrontera INC. | $54.54 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $52.18 | 2024 | Zoryve |
| Dermavant Sciences, INC. | $43.66 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $31.16 | 2021 | |
| Springworks Therapeutics, INC. | $25.89 | 2025 | Gomekli |
| Epi Health, LLC | $23.82 | 2021 | |
| Botanix Sb INC | $22.93 | 2025 | Sofdra |
| Almirall LLC | $22.80 | 2025 | Klisyri |
| Dermira, INC. | $22.48 | 2021 | |
| Glaxosmithkline, LLC. | $20.23 | 2023 | Arexvy, Shingrix |
| Kyowa Kirin, INC. | $19.37 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.